Roche ’s OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis

Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of OCREVUS for people with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for people with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news